Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.

Selenium (Se) is an essential trace element for selenoprotein biosynthesis. Selenoproteins have been implicated in cancer risk and tumor development. Selenoprotein P (SePP) serves as the major Se transport protein in blood and as reliable biomarker of Se status in marginally supplied individuals. Am...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hellmuth A Meyer, Tobias Endermann, Carsten Stephan, Mette Stoedter, Thomas Behrends, Ingmar Wolff, Klaus Jung, Lutz Schomburg
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a6d101e1e646478da136bc174c12b2d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6d101e1e646478da136bc174c12b2d0
record_format	dspace
spelling	oai:doaj.org-article:a6d101e1e646478da136bc174c12b2d02021-11-18T08:12:43ZSelenoprotein P status correlates to cancer-specific mortality in renal cancer patients.1932-620310.1371/journal.pone.0046644https://doaj.org/article/a6d101e1e646478da136bc174c12b2d02012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23056383/?tool=EBIhttps://doaj.org/toc/1932-6203Selenium (Se) is an essential trace element for selenoprotein biosynthesis. Selenoproteins have been implicated in cancer risk and tumor development. Selenoprotein P (SePP) serves as the major Se transport protein in blood and as reliable biomarker of Se status in marginally supplied individuals. Among the different malignancies, renal cancer is characterized by a high mortality rate. In this study, we aimed to analyze the Se status in renal cell cancer (RCC) patients and whether it correlates to cancer-specific mortality. To this end, serum samples of RCC patients (n = 41) and controls (n = 21) were retrospectively analyzed. Serum Se and SePP concentrations were measured by X-ray fluorescence and an immunoassay, respectively. Clinical and survival data were compared to serum Se and SePP concentrations as markers of Se status by receiver operating characteristic (ROC) curve and Kaplan-Meier and Cox regression analyses. In our patients, higher tumor grade and tumor stage at diagnosis correlated to lower SePP and Se concentrations. Kaplan-Meier analyses indicated that low Se status at diagnosis (SePP<2.4 mg/l, bottom tertile of patient group) was associated with a poor 5-year survival rate of 20% only. We conclude that SePP and Se concentrations are of prognostic value in RCC and may serve as additional diagnostic biomarkers identifying a Se deficit in kidney cancer patients potentially affecting therapy regimen. As poor Se status was indicative of high mortality odds, we speculate that an adjuvant Se supplementation of Se-deficient RCC patients might be beneficial in order to stabilize their selenoprotein expression hopefully prolonging their survival. However, this assumption needs to be rigorously tested in prospective clinical trials.Hellmuth A MeyerTobias EndermannCarsten StephanMette StoedterThomas BehrendsIngmar WolffKlaus JungLutz SchomburgPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e46644 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hellmuth A Meyer Tobias Endermann Carsten Stephan Mette Stoedter Thomas Behrends Ingmar Wolff Klaus Jung Lutz Schomburg Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
description	Selenium (Se) is an essential trace element for selenoprotein biosynthesis. Selenoproteins have been implicated in cancer risk and tumor development. Selenoprotein P (SePP) serves as the major Se transport protein in blood and as reliable biomarker of Se status in marginally supplied individuals. Among the different malignancies, renal cancer is characterized by a high mortality rate. In this study, we aimed to analyze the Se status in renal cell cancer (RCC) patients and whether it correlates to cancer-specific mortality. To this end, serum samples of RCC patients (n = 41) and controls (n = 21) were retrospectively analyzed. Serum Se and SePP concentrations were measured by X-ray fluorescence and an immunoassay, respectively. Clinical and survival data were compared to serum Se and SePP concentrations as markers of Se status by receiver operating characteristic (ROC) curve and Kaplan-Meier and Cox regression analyses. In our patients, higher tumor grade and tumor stage at diagnosis correlated to lower SePP and Se concentrations. Kaplan-Meier analyses indicated that low Se status at diagnosis (SePP<2.4 mg/l, bottom tertile of patient group) was associated with a poor 5-year survival rate of 20% only. We conclude that SePP and Se concentrations are of prognostic value in RCC and may serve as additional diagnostic biomarkers identifying a Se deficit in kidney cancer patients potentially affecting therapy regimen. As poor Se status was indicative of high mortality odds, we speculate that an adjuvant Se supplementation of Se-deficient RCC patients might be beneficial in order to stabilize their selenoprotein expression hopefully prolonging their survival. However, this assumption needs to be rigorously tested in prospective clinical trials.
format	article
author	Hellmuth A Meyer Tobias Endermann Carsten Stephan Mette Stoedter Thomas Behrends Ingmar Wolff Klaus Jung Lutz Schomburg
author_facet	Hellmuth A Meyer Tobias Endermann Carsten Stephan Mette Stoedter Thomas Behrends Ingmar Wolff Klaus Jung Lutz Schomburg
author_sort	Hellmuth A Meyer
title	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
title_short	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
title_full	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
title_fullStr	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
title_full_unstemmed	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
title_sort	selenoprotein p status correlates to cancer-specific mortality in renal cancer patients.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/a6d101e1e646478da136bc174c12b2d0
work_keys_str_mv	AT hellmuthameyer selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT tobiasendermann selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT carstenstephan selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT mettestoedter selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT thomasbehrends selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT ingmarwolff selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT klausjung selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients AT lutzschomburg selenoproteinpstatuscorrelatestocancerspecificmortalityinrenalcancerpatients
_version_	1718422064412491776

Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.

Ejemplares similares